09 . 03 .2026
Press release
Galderma introduces Cetaphil AM/PM Antioxidant Serums, a new science-driven defense and recovery system for sensitive skin
05 . 03 .2026
Press release
Galderma delivers record 2025 results with net sales of 5.207 billion USD, up 17.7% at constant currency, and Core EBITDA of 1.211 billion USD, growing 18.9% at constant currency
27 . 02 .2026
Press release
Galderma’s Nemluvio® (nemolizumab) demonstrates long-term disease control in prurigo nodularis up to three years
25 . 02 .2026
Press release
Galderma announces triple approval of new state-of-the-art Restylane® syringe in the EU, the U.S., and Canada, reaffirming the company’s position at the forefront of Injectable Aesthetics
20 . 02 .2026
News story
Expanding our global footprint with the new Kraków Global Capability Center
12 . 02 .2026
Press release
We Are All Sculptra: first-of-its-kind Galderma initiative to demonstrate how everyone can benefit from Sculptra’s regenerative properties
11 . 02 .2026
Press release
Galderma expands Restylane® portfolio in Japan with launch of OBT™ hyaluronic acid injectables Restylane Defyne™ and Refyne™
02 . 02 .2026
Press release
Galderma announces U.S. FDA acceptance of RelabotulinumtoxinA Biologics License Application resubmission
30 . 01 .2026
Press release
Galderma tackles menopause-related skin changes with global survey and clinical trial inclusivity